Background: Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation and PTLD. However, reports on the curative management of refractory PTLD are scarce.
Case presentation: In this report, we describe the successful management of two patients with EBV-PTLD with chimeric antigen receptor T-cell (CAR-T) therapy.
Conclusion: The present results demonstrated that patients with EBV-PTLD may benefit from CAR-T therapy and that the toxicity is manageable. Further studies are needed to verify these findings.
Keywords: ALL; CAR-T; EBV; HSCT; PTLD.
Copyright © 2021 Yan, Wang, Zhang, Wang, Mao, Peng, Kuang, Chen, Zhu, Zhou, Zhang and Cao.